Lesson plan

Novimmune

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998. Novimmune has six publicly disclosed drug in their pipeline: * NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017. * NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively. * NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016. * NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases. * NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. * NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. No drugs have been approved yet.

Back to article

Article summary

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998. Novimmune has six publicly disclosed drug in their pipeline: * NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017. * NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively. * NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016. * NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases. * NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. * NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. No drugs have been approved yet.

Key claims

  1. date of foundation: 1998 — source: Wikipedia, revision 1314574453, retrieved 2026-10-20 · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the date of foundation is "1998". What evidence would count against this claim?
  3. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  4. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia, “Novimmune”, revision 1314574453, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1314574453

Key claims and bibliography are generated from the same tracked claims and sources as the article page.